© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dapagliflozin didn’t appear out of nowhere. Discovery teams tried many approaches to treat diabetes, searching for a therapy that could lower blood sugar without demanding constant glucose monitoring or posing the risk of low blood sugar. Back in the early 2000s, scientists realized blocking the renal sodium-glucose co-transporter—also called SGLT2—might let the body dump extra sugar through urine. Bristol-Myers Squibb and AstraZeneca pushed Dapagliflozin through the long climb of laboratory work and clinical trials. Regulatory approval involved hard scrutiny after early studies flagged rare bladder cancer cases, but researchers pressed ahead, proving clinical benefits outweighed the theoretical risks. It earned official green lights for Type 2 diabetes and later expanded for use in people with heart failure—showing how drug development rarely follows a straight path, but rewards real perseverance.
Pharmacies now stock Dapagliflozin Monohydrate as a tablet, usually labeled under brand names like Farxiga or Forxiga. It treats adults with Type 2 diabetes, either alone or in combination with other glucose-lowering agents. Beyond sugar control, doctors have turned to it for people facing a high risk of cardiovascular events. The action comes from helping kidneys throw out sugar in urine, keeping blood sugar lower without burdening the pancreas. Tablet strengths commonly hit the market as 5mg or 10mg doses, reflecting a need for flexibility with patient needs or tolerability. Packages and inserts must carry detailed information on its indications, side effects, and precautions, in line with regulatory demands for safety and transparency.
Dapagliflozin Monohydrate appears as a white or almost-white crystalline powder. It's not much attracted to water, meaning it won’t easily dissolve, which influences how manufacturers design the tablet. The chemical formula stands as C21H25ClO6∙H2O, linking the core dapagliflozin molecule with a molecule of water. Boiling point and melting point specifics turn out to be less useful for the average clinician than for a production chemist, but the drug remains stable at room temperature, surviving storage in pill bottles and pill packs.
Each blister or bottle must show batch number, manufacture date, and shelf life. European Pharmacopeia standards require purity greater than 98% for the active ingredient, and recognized pharmacopoeias outline strict limits on impurities. Tablets bear a code for easy identification and usually sport clear markings to help patients avoid mix-ups. The U.S. FDA, EMA, and Chinese NMPA have harmonized many of these technical standards to cut down on confusion across borders. Labels warn about serious possible side effects, including dehydration, yeast infections, urinary tract infections, and risk of diabetic ketoacidosis. Healthcare workers read this information to track down side effects before they turn threatening.
Chemists build Dapagliflozin Monohydrate using a multi-step sequence. Synthesis involves the selective glycosylation of a protected glucose to link it with a phenyl-substituted benzyl alcohol backbone. Reactions often use palladium-catalyzed coupling, then acid or base to strip protecting groups. The monohydrate form, favored for its physical stability, comes by adding precise amounts of water during the final purification. Crystallization under controlled temperature and humidity creates a form that resists clumping, enabling accurate dosing in tablet production lines. Pharmaceutical plants use quality-by-design practices to watch each batch and pull any that fall outside specification.
Scientists have played with the dapagliflozin structure, testing different substitutions to tweak how it binds the SGLT2 protein. Halogenation changes, small shifts in side-chains, and glycosidic bond variations shifted activity and absorption. SGLT2 inhibitors share a similar backbone, yet minor chemical differences between dapagliflozin, canagliflozin, and empagliflozin tilt their selectivity, duration in the body, and risk of side effects. Academics continue to probe new derivatives to improve selectivity, seeking better safety when used long-term.
Dapagliflozin Monohydrate goes by many names in research and commerce. Scientific papers often write it as DAP, Benzyl (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, or call it by its Research Code BMS-512148. Drug shops stock it as Farxiga or Forxiga, and generics have started listing other brand identities, depending on the country of sale. Cross-checking between synonyms helps prevent prescription errors and confusion between products, making this information vital for pharmacy staff stocking shelves.
Production workers need gloves and respirators since the powder can cause allergic reactions if inhaled or touched. Manufacturing lines follow Good Manufacturing Practices (GMP) to prevent product contamination, and waste must be neutralized before disposal. Hospital nurses pay attention to dosing to prevent low blood sugar events, dehydration, or rare but severe ketoacidosis. Federal guidance requires routine clinical monitoring for kidney function, electrolyte levels, and early signs of urinary tract or genital infections.
Most prescriptions go to people with Type 2 diabetes, especially those who don’t reach their sugar goals with metformin or want to avoid the risk of weight gain. Cardiologists began prescribing it after large-scale studies revealed benefits in heart failure, even among people without diabetes. The drug now shows up in nephrology clinics to slow down the loss of kidney function in people with chronic kidney disease. Some clinicians have proposed using it as part of primary prevention in people with high cardiovascular risk, expanding interest beyond diabetes alone.
Dapagliflozin entered the market after a string of studies, including DECLARE-TIMI 58 and DAPA-HF trials, which mapped how the drug reduced heart attacks, hospitalizations, and deaths for high-risk patients. Early development measured glucose-lowering power, and later work dug into kidney disease and heart failure. Companies now run trials combining dapagliflozin with other drugs—looking for additive effects or ways to treat those who don’t respond to single therapy. Ongoing lab work explores other transporter targets in the same chemical family, searching for the next step in therapy evolution.
Animal models didn’t show major toxicity at doses far above what humans would ever see, but long-term exposure studies made safety teams watch for subtle effects, especially in urinary or reproductive systems. Regulators required close monitoring when early data suggested a possible rise in bladder cancer, though later work kept this risk in context and showed benefits for most patients. Healthcare professionals stay alert to post-marketing data, recognizing that rare side effects turn up after millions receive the medicine, not just the few thousand in clinical trials.
Science keeps pushing dapagliflozin beyond diabetes. Pharmaceutical investigators study its use across a range of kidney diseases, exploring outcomes for patients at risk of fast decline in kidney function, regardless of sugar status. More teams have begun to explore the use of SGLT2 inhibitors in combination with GLP-1 agonists and other modern agents to change the landscape for metabolic disease. Over the next decade, expect the story of dapagliflozin to grow, covering new diseases and improved formulations that lower barriers to treatment and reach wider groups.
The number of people living with type 2 diabetes climbs higher each year. This isn’t just a statistic—these are real lives shaped by daily finger pricks, endless pillboxes, and worries about future complications. Out of all the medications out there, dapagliflozin monohydrate stands out. People know it by brand names like Farxiga. I’ve seen close family members use it, and the effect goes beyond blood sugar numbers on a chart.
Doctors use this medicine in a way that feels different compared to older diabetes drugs. Rather than nudging the pancreas to crank out more insulin, dapagliflozin acts on the kidneys. It prompts them to flush excess sugar out in the urine. This can lower blood sugar without risking swings that drop glucose too low—something that makes daily living less of a balancing act for many.
Research has shown dapagliflozin isn’t just about glucose. In my experience, and after talking to healthcare professionals, the heart benefits really matter. A landmark study called DECLARE-TIMI 58 tracked more than 17,000 people. Not only did the drug help control blood sugar, but it also cut the risk of hospital visits for heart failure. For someone whose father has dealt with both diabetes and heart disease, that’s real news.
People using dapagliflozin report slight weight loss, which can improve confidence and well-being. Lower blood pressure often follows suit. This combination checks a lot of boxes for people fighting metabolic syndrome in all its forms—obesity, high cholesterol, and hypertension. For folks at risk, every point shaved off blood pressure or pounds lost isn’t a trivial thing.
Kidney protection looks promising too. Waiting for dialysis becomes much less likely with drugs like dapagliflozin. This gives patients and families real hope for maintaining independence as years go by.
No one should treat this drug as a miracle. Dapagliflozin does bring side effects—more frequent urination, a higher chance of urinary tract infections, and concerns for people with severe kidney problems. The cost also counts; insurance does not pay equally for everyone, leaving some people deciding between medication and groceries.
Education gaps sting the most. In many clinics, patients don’t hear about dapagliflozin’s benefits unless they push for answers. I’ve watched family members rely on overworked doctors who lean on older prescriptions by habit. So, people stay stuck with out-of-date regimens that don’t offer the same protection.
Doctors and nurses should talk openly about new choices like dapagliflozin. Patients need a clear explanation of side effects, possible costs, and the advantages for heart and kidney health. Technology can help with pharmacy programs that lower out-of-pocket payments. Professional societies continue to collect data and issue clearer guidelines, so no one gets left in the dark about the best ways to manage their risk.
Real-life changes need trust and teamwork between patients, families, and their health providers. Dapagliflozin makes that easier, letting people focus less on complications and more on living well.
Managing diabetes includes more than checking blood sugar and following a meal plan. Many rely on medicines like dapagliflozin monohydrate to help control their numbers. This medication works by helping the kidneys get rid of excess glucose through urine. For most, it shows real promise in lowering blood sugar and protecting the heart and kidneys. Still, like nearly any drug, taking dapagliflozin often brings unwanted effects alongside its benefits.
Doctors and pharmacists often talk about increased urination. It makes sense, considering how dapagliflozin sends more glucose out with urine. Some people start planning their days around finding the nearest restroom, especially in the first week. Thirst often tags along since fluid loss through urine leads to dry mouth and dehydration. A tall glass of water helps, but thirst can get old fast.
Yeast infections often come up in discussions. Higher sugar levels in urine create a welcoming spot for yeast, especially in women. Men sometimes deal with irritation or redness. While these infections usually clear up with over-the-counter treatments, repeated episodes get frustrating and can bring embarrassment or discomfort. Doctors tend to warn patients right away to keep an eye out for itching or any unusual discharge.
Some people feel a dip in energy, mostly tied to dehydration. Dizziness stands out, especially for those combining dapagliflozin with blood pressure medicine. Seniors or those working in hot environments should pay extra attention to signs of low blood pressure — feeling faint, lightheaded, or confused. Good hydration may help keep things steady, but close attention to the body's signals always matters.
Rare doesn’t always mean “never.” Certain infections like Fournier’s gangrene (a kind of flesh-eating disease in the groin area) have shown up in medical literature. Reports stay uncommon, but every person deserves to know what’s possible before starting the medicine. Early medical care helps a lot if something feels very wrong.
Ketoacidosis stands as another red flag. Here, blood turns acidic due to chemicals called ketones. Some cases surface even in people with type 2 diabetes — a surprise for doctors and patients alike. Symptoms include nausea, vomiting, stomach pain, trouble breathing, or confusion. Blood tests at routine visits can track for trouble, and anyone using dapagliflozin should know to call for help if these signs appear.
Heart failure and kidney protection give dapagliflozin the edge over many older diabetes drugs. For the millions at risk of kidney decline, new research shows fewer trips to the hospital and fewer cases of kidney failure when on this medicine. That’s the tradeoff: weighing stronger protection for the long haul against the bumps in the road from side effects.
Open and honest conversations with healthcare providers lead to better results. Hydration, regular check-ins, and clear reporting of any new symptoms keep patients out of trouble. Pharmacists and diabetes educators play a huge part. They talk about what to expect, how to treat mild problems, and when a side effect needs urgent care instead of a band-aid. Staying aware of side effects doesn’t just keep things safe — it keeps people out of the hospital and lets them enjoy more healthy days.
Dapagliflozin monohydrate stands as a key medicine for those living with type 2 diabetes and certain kinds of heart failure. As someone who has spent years learning from doctors, pharmacists, and real people from diabetes support groups, I've noticed questions pop up about exactly how to take this drug. Some folks get nervous, thinking about how a small change in routine could affect blood sugar or the heart. This isn’t just about swallowing a pill. It’s about safety, keeping blood sugar in check, and giving your heart the support it deserves.
Medical guidelines and experienced doctors all lean toward once-daily doses, often in the morning. This helps with remembering, whether it’s with breakfast, before work or school, or after brushing teeth. For folks already on other diabetes medicine, integrating dapagliflozin monohydrate into that routine usually brings fewer headaches. The tablets don’t care about food, so it’s usually safe to take them with or without a meal. Swallowing the tablet whole with water is the way to go—crushing or splitting can throw off the way the medicine works.
Missing medication happens, even to the most disciplined. Instead of stressing, the common advice is to take the missed dose as soon as possible if you’re not too close to the next dose. Never double up. Skipping, then doubling, tends to mess things up and can push blood sugar either too low or too high—something no one wants.
Doctors don’t just pick dosing numbers out of thin air. They look at kidney function, heart conditions, and other medicines in a person’s daily lineup. In my experience listening to specialists, a close look at lab results guides these choices. Folks with chronic kidney issues often need adjustments. If kidney function drops a lot, dapagliflozin may need to be stopped entirely. Patients who don’t check in regularly can miss these critical changes.
Dapagliflozin helps, but it doesn’t come free of risk. Dehydration sneaks up sometimes, especially in hot weather or when illness strikes with vomiting or diarrhea. Getting enough fluids everyday, especially water, offers real protection. Infections in the urinary tract or genitals can show up more often too. These risks go up for folks who forget personal hygiene, or who wait too long to report early symptoms. Patient education makes a big difference—when you know what signs to look for, you stay in front of problems rather than behind them.
No one should take dapagliflozin monohydrate in a vacuum. Regular chats with a healthcare team catch issues early, whether it’s unexpected thirst, a new infection, or changes in urine habits. Talking honestly about symptoms, routines, and even worries helps doctors fine-tune the plan. Pharmacists can break down complicated instructions better than a printed label and are happy to explain anything in plain language.
Managing chronic illness can get lonely. Family, friends, support groups, and health workers all have a role to play. In every group I’ve learned from, people who ask questions and admit mistakes figure things out faster, and dodge more trouble. Dapagliflozin gives people with diabetes and certain heart issues an extra tool for health, but it works best for those who ask for backup when they need it.
Living with diabetes rarely feels simple. Most people I’ve known on this journey juggle more than a single pill or shot. Doctors often talk about “combination therapy” for a reason—it’s rarely just one problem, and trying to handle blood sugar, weight, blood pressure, and kidney health all at once means a lot of moving parts. Dapagliflozin monohydrate, often recognized by its brand name Farxiga, fits into this puzzle. It belongs to a class called SGLT2 inhibitors, which help get rid of extra glucose through urine.
Metformin might be the most familiar starting point for adults with type 2 diabetes. It’s been prescribed for decades, and in my experience, most people’s doctors reach for it first due to its safety and cost. But life and bodies get complicated. Over time, many people notice their blood sugars creeping up again, even if they never miss a dose. That’s where adding another medicine, like dapagliflozin, can make sense.
Studies back this up. Adding dapagliflozin to metformin gets blood sugar down better than metformin alone. What stands out is not just lower A1C, but the extra benefits. Folks often lose a few pounds and see blood pressure drop a bit. That’s good news for a group at high risk for heart and kidney problems. I’ve seen firsthand how new meds worry people, but knowing a medicine can help in more than one way builds trust.
Some people struggle with high sugars even on both metformin and a sulfonylurea, or even daily insulin shots. Dapagliflozin works by an entirely different route, so doctors can add it to these combinations, too. Watching someone cut down their insulin dose or suffer fewer swings in blood sugar can turn a hard day around. This isn’t just theory—clinical studies show that dapagliflozin can lower A1C and help shed a bit of weight even in people already on insulin therapy.
Of course, combining medicines calls for caution. There’s a higher chance of certain side effects, especially a kind of yeast infection or urinary tract infection, since the medicine causes more sugar in the urine. People taking sulfonylureas or insulin plus dapagliflozin also need to keep an eye out for low blood sugar. That’s where a strong relationship with a healthcare provider matters most. Quick follow-ups, honest reporting of symptoms, and a willingness to ask for clarification will keep you safe.
Adding another medication feels like one more piece of mental load. People living with diabetes already need to check their sugars, plan meals, and remember appointments. The added benefits of combining dapagliflozin with other meds—like drops in blood pressure or protection for the kidneys—mean a lot. But costs can add up, and each person’s insurance or pharmacy benefits look different.
Education makes a difference. Anyone considering dapagliflozin alongside their other meds should hear from a pharmacist or diabetes team about potential interactions, what side effects to report, and signs of trouble like dehydration or unusual fatigue. In my work with people managing chronic illness, I see the biggest gains in those who simply know what to expect.
No single solution fits all. Doctors weigh A1C, heart and kidney health, weight, medication habits, and quality of life. Some people need fewer pills; others need every tool available. Dapagliflozin opens up new options—especially for adults struggling despite their best efforts. Knowing the facts and keeping communication open makes a big difference, letting patients and their teams adjust treatment as life changes.
Dapagliflozin monohydrate makes a difference for a lot of people with type 2 diabetes. It helps manage blood sugar and can even aid folks with heart failure. The benefits show up in major clinical studies, and many doctors trust it. Not everyone gets the green light, though. Some people face bigger risks than rewards.
Anyone with low kidney function needs to talk with their healthcare team before trying dapagliflozin. This drug works by helping the kidneys flush out sugar through urine. If kidneys aren’t working well, pushing them further can be dangerous. I’ve seen nephrologists warn patients: numbers don’t lie. If your estimated glomerular filtration rate (eGFR) drops below 30, this drug isn’t safe. For some, even milder kidney impairment brings unpredictable effects.
Ketoacidosis rarely hits people with type 2 diabetes, but it does happen. Dapagliflozin makes the body shed sugar in urine, which drops blood sugar and shifts metabolism. Under stress or infection, this action can nudge some folks toward a dangerous buildup of acids (ketones) in the blood. The FDA has flagged this risk, and endocrinologists agree: people with a history of ketoacidosis should steer clear. Even those with low or normal sugars can go into ketoacidosis with this medication.
It’s tempting for some people with type 1 diabetes to ask about dapagliflozin. They see promising headlines or hear about extra weight loss. The evidence just doesn’t support its use in this group. The risk of ketoacidosis overshadows any benefit. Regulatory agencies haven’t approved it for type 1. A friend once put it bluntly: “It’s not worth the experiment.” Nobody wants a hospital stay just for tighter numbers on a glucometer.
Pregnancy changes everything for diabetes. Dapagliflozin hasn’t been tested enough in pregnant or nursing mothers, and animal studies suggest risks for the developing baby’s kidneys. Physicians won’t take chances with a baby’s health—there are safer medication options. Women who plan to become pregnant soon should also talk with their care team. That conversation matters, because early pregnancy risks are real and irreversible.
By pushing extra sugar into the urine, this drug fuels yeast and bacteria. Some people deal with recurrent yeast infections, urinary tract infections, or both. In real-world settings, patients speak up about this frustrating side effect. Anyone who gets these infections often might want to avoid dapagliflozin or at least take extra steps to reduce the odds—good hygiene, drinking plenty of water, and staying in close contact with a healthcare provider.
A handful of people experience allergic reactions—rashes, swelling, trouble breathing. It’s rare, but it happens. Doctors will stop the medication immediately at the first sign of allergy. Regular follow-up for anyone starting a new drug, especially with a prior history of allergies, keeps things safer.
Some folks fit in more than one of these groups. Every person has different needs and responses when dealing with chronic conditions. Communicating openly with the care team, reporting side effects, and tracking bloodwork sets up safer outcomes. Dapagliflozin helps many, but for others, different medications or lifestyle changes offer a better path.
| Names | |
| Preferred IUPAC name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)-3,4,5-trihydroxyoxane-2-carboxylic acid; monohydrate |
| Other names |
Dapagliflozin Propanediol Monohydrate Forxiga Farxiga BMS-512148-01 |
| Pronunciation | /ˌdæp.əˌɡlɪfˈlɔː.zɪn ˌmɒn.oʊˈhaɪ.dreɪt/ |
| Identifiers | |
| CAS Number | 1206123-37-6 |
| Beilstein Reference | 5202753 |
| ChEBI | CHEBI:134922 |
| ChEMBL | CHEMBL2364603 |
| ChemSpider | 10486543 |
| DrugBank | DB06292 |
| ECHA InfoCard | 07c578a4-7458-4aab-9885-25c6fa6e7b48 |
| EC Number | NA |
| Gmelin Reference | 1164580 |
| KEGG | D10268 |
| MeSH | D015179 |
| PubChem CID | 11508236 |
| RTECS number | VW8XUQ6S0H |
| UNII | 2N9C93E14N |
| UN number | UN Number not assigned |
| CompTox Dashboard (EPA) | DTXSID10539963 |
| Properties | |
| Chemical formula | C21H25ClO6·H2O |
| Molar mass | Molar mass: 408.87 g/mol |
| Appearance | White to yellowish-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 1.8 |
| Acidity (pKa) | pKa = 13.1 |
| Basicity (pKb) | 12.36 |
| Magnetic susceptibility (χ) | -86.0e-6 cm³/mol |
| Refractive index (nD) | 1.54 |
| Dipole moment | 3.7196 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 321.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -3586 kJ/mol |
| Pharmacology | |
| ATC code | A10BK01 |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H312: Harmful in contact with skin. H332: Harmful if inhaled. |
| Precautionary statements | Keep out of reach of children. For oral use only. Store in a cool, dry place below 30°C. Protect from moisture and sunlight. Use only as directed by your physician. Do not use if package is damaged. Dispose of unused medicine properly. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| Flash point | > 198.1 °C |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >2000 mg/kg (rat, oral) |
| NIOSH | DTALXANBNLIQRJ-UHFFFAOYSA-N |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 50 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Dapagliflozin Empagliflozin Canagliflozin Ertugliflozin Sotagliflozin Tofogliflozin Luseogliflozin Ipragliflozin |
